ClinicalTrials.gg
RecruitingNCT05857631PARCERIIUpdated Apr 15, 2025

Postoperative Hypofractionated Radiation in Cervical and Endometrial Tumours: Phase II Study

An interventional study of Hypofractionated Image guided External Beam Radiation Therapy (EBRT) and Cisplatin in Cervical Cancer and Endometrial Cancer, sponsored by Tata Memorial Centre. Recruiting at 2 sites in India. Open to female participants aged 18 Years to 80 Years. Per ClinicalTrials.gov, last updated 2025-04-15.

Sponsored by Tata Memorial Centre · Not applicable, Interventional, and Treatment

How we know

From the registry’s dates

  • Started May 2023; still recruiting 3 years 5 months later.

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Not applicable
Study type
Interventional
Enrollment
90
Allocation
Not applicable
Ages
18 Years to 80 Years
Sex
Female
01

Where this study stands

Counted across the records on this site · 2026-11-22

Among 80 studies testing cisplatin in Uterine Cervical Neoplasms — 10 open to participants now, 11 under way, 3 of them phase 3. Cisplatin · Uterine Cervical Neoplasms.

Planned enrollment
21st of 73
90 · median 50
Started
2023
with 1 other
No phase
7 of 80
4 open now
Primary completion
2029-05
later than 9 of 10 live
Registered
77th of 80
by date

Among the 80 studies testing cisplatin in Uterine Cervical Neoplasms, this one is the 21st largest by planned enrollment of the 73 interventional ones that give a count, is one of 2 that started in 2023, is one of 7 with no phase, reaches primary completion later than 9 of the 10 other live ones, and was the 77th registered.

Uterine Cervical Neoplasms

2,369 studies on the registry are indexed under Uterine Cervical Neoplasms; 678 are open to participants now.

Browse Uterine Cervical Neoplasms studies →

Open to participants now

10 of the 80 studies testing cisplatin in Uterine Cervical Neoplasms are open now, in 6 countries. Recruiting first, the newest first:

4 more — sign in →

By country, each count listing its studies:

All 10 open studies →

About cisplatin

Cisplatin: first FDA approval 1978 (PLATINOL-AQ). What it is approved for, and how studies give it, is on its page →

Who these studies take

Of the 476 Uterine Cervical Neoplasms studies recruiting now, 245 (51%) set no upper age limit and 191 (40%) stop at 75 or younger; 20 take children under 18; 68 take healthy volunteers.

This study: 18 Years to 80 Years · female · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 80 studies testing cisplatin in Uterine Cervical Neoplasms, or all of them as a file.
02

Study summary

The primary aim of the trial is to investigate the late effects of hypofractionated external radiation (39 Gy in 13 fractions) in patients requiring post-operative radiation for early-stage cervical and endometrial cancers.

Read the detailed description

This is a phase II prospective study that will be accruing patients with post operative cervical or endometrial cancer requiring adjuvant pelvic radiation.

External beam radiotherapy (Intensity modulated radiotherapy/arc technique) will be delivered to pelvis to a dose of 39 Gray (Gy) in 13 fractions at 3 Gy per fraction, delivered once daily over 2.5 - 3 weeks. Treatment will be delivered with Intensity Modulated Radiotherapy (IMRT) under image guidance. Patients for whom concurrent chemotherapy is indicated (as per adverse risk features) will receive concurrent weekly cisplatin (40mg/m2) based on standard institutional protocol. All patients with post-operative cervical cancer will receive vaginal brachytherapy after the completion of external beam radiation. Patients with endometrial cancer with certain pre defined risk factors will also receive vaginal brachytherapy. The dose of vaginal brachytherapy will be 6 Gy high dose rate brachytherapy delivered as two different fractions, one week apart. Patients will be evaluated by the concerned investigators on a weekly basis during radiation therapy and all the toxicities will be documented according to the CTCAE V 5.0.

Patients will be followed up 3 monthly for the first 2 years, then 6 monthly from years 2 - 5, and annually thereafter. CTCAE version 5 will be used for toxicity grading at each follow-up. Quality of life assessment will be performed at baseline prior to the start of radiation and on follow-up at pre-specified times using the European Organization for Research and Treatment of Cancer Quality of Life Questionnaire (QLQ-C30) and Cervix - 24 (CX24) for cervical cancer patients and Endometrium 24 (EN24) for endometrial cancer patients.

03

Conditions studied

  • Cervical Cancer
  • Endometrial Cancer

Keywords

  • Hypofractionated Radiation
  • Radiotherapy, Adjuvant
  • Radiotherapy, Intensity modulated
  • Late gastrointestinal and genitourinary toxicities
04

Who can participate

Ages eligible
18 Years to 80 Years
Sexes eligible
Female
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  1. (ECOG) performance status of 0 to 2
  2. confirmed diagnosis of cervical cancer post hysterectomy with intermediate or high-risk features, requiring adjuvant EBRT ± concurrent chemotherapy OR histologically confirmed diagnosis of endometrial cancer post hysterectomy requiring (chemo)radiotherapy to pelvis with/without vaginal brachytherapy.

Exclusion criteria

Exclusion Criteria:

  1. Patients with macroscopic residual disease (R+ resection) postoperatively
  2. Patients requiring extended field radiotherapy (patients with involved para-aortic lymph nodes in cervical or endometrial cancer)
  3. Patients treated with chemotherapy for any prior at any time
  4. Patients treated with pelvic radiation previously
  5. Patients with infection
  6. Any preexisting medical conditions that may interfere with the assessment of genitourinary or gastrointestinal toxicity (This includes patients with irritable bowel syndrome, subacute intestinal obstruction, anal incontinence, hemorrhoids precluding analysis of gastro-intestinal toxicities, urinary incontinence, recurrent urinary tract infections)
Terms in these criteria, in plain language(5)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

ECOG performance status

A scale of how much an illness limits everyday activity. For people being assessed to join a study, scores run from 0 (fully active) to 4; lower is more active.

0
Fully active, no restrictions.
1
Limited in strenuous activity, but walking and able to do light work, such as housework or office work.
2
Walking and able to look after yourself, but unable to work; up and about more than half of waking hours.
3
Able to look after yourself only in part; in bed or a chair more than half of waking hours.
4
Unable to look after yourself at all; in bed or a chair all day.

Studies most often ask for 0–1 or 0–2. Your doctor gives the score; the WHO scale uses the same steps. The full scale also has 5, which records death.

Histologically or cytologically confirmed

The diagnosis was confirmed by looking at a sample under a microscope: tissue from a biopsy or surgery (histology), or cells from a fluid or needle sample (cytology).

Your pathology report is the document that shows this.

Adjuvant and neoadjuvant

Neoadjuvant treatment is given before the main treatment (usually surgery), often to shrink a tumor. Adjuvant treatment is given after it, to lower the chance of the cancer coming back.

Cancer (malignancy)

Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.

Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.

HIV

The human immunodeficiency virus, which weakens the immune system.

Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.

05

Study design

Phase
Not applicable
Primary purpose
Treatment
Allocation
Not applicable
Intervention model
Single group
Masking
None (open label)
Enrollment
90 participants (estimated)

Study arms

  • Experimental
    Hypofractionated Image guided External Beam Radiation

    Adjuvant hypofractionated external beam radiotherapy for post operative patients with cervical or endometrial cancer.

    Radiation: Hypofractionated Image guided External Beam Radiation Therapy (EBRT) · Drug: Cisplatin · Radiation: Vaginal brachytherapy

Interventions

  • RadiationHypofractionated Image guided External Beam Radiation Therapy (EBRT)

    External beam radiotherapy to pelvis: Post operative hypofractionated external beam radiotherapy with intensity modulated/arc technique, to a dose of 39 Gy in 13 fractions, at 3 Gy per fraction, delivered once daily, 5 days a week, over 2.5-3 weeks.

    Also known as: Radiotherapy

  • Patients who require adjuvant chemotherapy along with radiation, based on predefined risk features, will receive 5 cycles of cisplatin on a weekly basis with a dose of 40 mg/m2 by IV infusion over a period of 1 hour 2-4 hours prior to start of EBRT.

    Also known as: Chemotherapy

  • RadiationVaginal brachytherapy

    Vaginal brachytherapy, two fractions of 6 Gy each, delivered 1 week apart.

    Also known as: Brachytherapy

06

What researchers measure

Primary outcomes

  1. 3-year cumulative incidence of grade ≥2 gastrointestinal or genitourinary toxicity

    To evaluate the 3-year cumulative incidence of late grade ≥2 gastrointestinal or genitourinary toxicity using CTCAE version 5 scoring receiving radiation with hypo fractionation.

    Time frame: Median follow up of 3 years

Secondary outcomes

  1. Pelvic Control Rate at 3 years

    To report 3 year pelvic control rate (local and pelvic nodal) in patients receiving hypofractionated radiotherapy.

    Time frame: Median follow up of 3 years

  2. Disease Free Survival at 3 years

    To report 3 year disease free survival in patients receiving hypo fractionated radiotherapy.

    Time frame: Median follow up of 3 years

  3. Overall Survival at 3 years

    To report 3 year overall survival in patients receiving hypo fractionated radiotherapy.

    Time frame: Median follow up of 3 years

  4. Acute Toxicities Evaluation

    Acute toxicity will be reported using CTCAE V. 5.0

    Time frame: 3 months

  5. Assessment of Quality of Life for cervical cancer patients

    To assess quality of life in using EORTC QLQ-C30 and CX24. Quality of life will be measured using the EORTC QLQ C-30. For cervical cancer, EORTC QLQ CX24 module will be used. QOL scoring will be done as per standard recommendations outlined in EORTC QLQ C30 scoring manual. All patients will undergo QOL evaluation at baseline, after treatment and at subsequent follow-up.Scale- Not at all-1 , A little Bit-2, Quite a bit-3, very much-4. 1 will be considered as better outcome \& 4 will be considered as worst outcome.

    Time frame: Median follow up of 3 years

  6. Assessment of Quality of Life for endometrial cancer patients

    To assess quality of life in using EORTC QLQ-C30 and EN24. Quality of life will be measured using the EORTC QLQ C-30. For endometrial tumours, EORTC QLQ EN24 will be used. QOL scoring will be done as per standard recommendations outlined in EORTC QLQ C30 scoring manual. All patients will undergo QOL evaluation at baseline, after treatment and at subsequent follow-up.Scale- Not at all-1 , A little Bit-2, Quite a bit-3, very much-4. 1 will be considered as better outcome \& 4 will be considered as worst outcome.

    Time frame: Median follow up of 3 years

  7. C-MOSES scoring

    To report cumulative toxicity score as assessed by C-MOSES scoring. Month and Severity Score (MOSES) will be calculated for each symptom (13 gastrointestinal and 6 genitourinary) with time weighted CTCAE toxicity, by using duration of time spent in each toxicity. Cumulative-MOSES score will be assessed for organ system (gastrointestinal and genitourinary), by summating MOSES of individual adverse event items respectively.

    Time frame: Median follow up of 3 years

07

Study locations

2 of 2 sites recruiting
08

References and documents

Individual participant data

Plan to share: No

No publications or documents are linked to this record.

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Started May 2023 (actual). Primary completion is estimated for May 2029, 71 months after the start.

Of 446 non-industry interventional studies with no phase under Uterine Cervical Neoplasms, half reached primary completion within 33 months of starting (the median), counting those still running; a quarter within 14 and three quarters within 71. This study's planned 71 months is above that.

Counting every sponsor, half of 462 studies reached it within 33 months; a quarter within 15 and three quarters within 71.

How these figures are worked out, and which studies are left out of them.

Registered
Mar 30, 2023
First posted
May 12, 2023
StartActual
May 29, 2023
Primary completionEst.
May 25, 2029
CompletionEst.
May 25, 2029
Last update
Apr 15, 2025
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Apr 15, 2025, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT05857631
Lead sponsor
Tata Memorial Centre
Responsible party
Prachi Mittal, MD, Radiation Oncology (Assistant Professor, Tata Memorial Centre) — Principal investigator
First posted
May 12, 2023
Start date
May 29, 2023
Primary completion
May 25, 2029 (estimated)
Completion
May 25, 2029 (estimated)
Last update
Apr 15, 2025

Study contacts

Dr. Prachi D Mittal, MD
Contact
mittalprachi@gmail.com
+91 9004938871
Dr. Prachi D Mittal, MD
principal investigator · Tata Memorial Hospital

Oversight

Data monitoring committee
Yes
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

Contact study team

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Cisplatin

Start the discussion